Evidence map›Paper›PMID 38548803›Full record

ArticleScientific reports2024

Evaluating a combination treatment of NK cells and reovirus against bladder cancer cells using an in vitro assay to simulate intravesical therapy.

Yuree Lim, Jeehun Park, Joung Eun Lim, Minji Park, Seung Kwon Koh, Mijeong Lee, Sang-Ki Kim, Seung-Hwan Lee, Ki-Hoon Song, Dong Guk Park and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yuree LimDepartment of Biopharmaceutical Convergence, Sungkyunkwan University (SKKU), Suwon, Korea.
Jeehun ParkDepartment of Molecular Bioscience, College of Biomedical Science, Kangwon National University, Chuncheon, Korea.
Joung Eun LimDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Minji ParkDepartment of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, South Korea.
Seung Kwon KohDepartment of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, South Korea.
Mijeong LeeDepartment of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, South Korea.
Sang-Ki KimDepartment of Companion & Laboratory Animal Science, Kongju National University, Yesan, Korea.
Seung-Hwan LeeDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Ki-Hoon SongViroCure Inc., Seoul, Republic of Korea.
Dong Guk ParkViroCure Inc., Seoul, Republic of Korea.
Hyun-Young KimDepartment of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea.
Byong Chang JeongDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. bc2.jung@samsung.com.
Duck ChoDepartment of Biopharmaceutical Convergence, Sungkyunkwan University (SKKU), Suwon, Korea. duck.cho@skku.edu.

Funding

Korea government (MSIT) RS-2023-00218543Ministry of Agriculture, Food and Rural Affairs 322092-4Ministry of Education, Science and Technology 2021R1A2B5B0100214911Ministry of Education, Science and Technology 2022R1I1A1A01063081Ministry of Health & Welfare, Republic of Korea HI22C1363
6 · The paper itself

Abstract

Intravesical treatment using either reovirus or natural killer (NK) cells serves as an efficient strategy for the treatment of bladder cancer cells (BCCs); however, corresponding monotherapies have often shown modest cytotoxicity. The potential of a locoregional combination using high-dose reovirus and NK cell therapy in an intravesical approach has not yet been studied. In this study, we evaluated the effectiveness of reoviruses and expanded NK cells (eNK) as potential strategies for the treatment of bladder cancer. The anti-tumor effects of mono-treatment with reovirus type 3 Dearing strain (RC402 and RP116) and in combination with interleukin (IL)-18/-21-pretreated eNK cells were investigated on BCC lines (5637, HT-1376, and 253J-BV) using intravesical therapy to simulate in vitro model. RP116 and IL-18/-21-pretreated eNK cells exhibited effective cytotoxicity against grade 1 carcinoma (5637 cells) when used alone, but not against HT-1376 (grade 2 carcinoma) and 253J-BV cells (derived from a metastatic site). Notably, combining RP116 with IL-18/-21-pretreated eNK cells displayed effective cytotoxicity against both HT-1376 and 253J-BV cells. Our findings underscore the potential of a combination therapy using reoviruses and NK cells as a promising strategy for treating bladder cancer.

Indexed as

CarcinomaOrthoreovirusReoviridaeUrinary Bladder NeoplasmsCombined Modality TherapyHumansInterleukin-18Killer Cells, NaturalInterleukin-18

Identifiers

PMID38548803
PMCPMC10979019

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.